105
COMPARATIVE ANALYSIS OF BASAL CELL AND SQUAMOUS CELL
CARCINOMA: CLINICAL, HISTOPATHOLOGICAL, AND
THERAPEUTIC PERSPECTIVES
Omonov E.F. student of group 411B, Faculty of Dentistry, Tashkent State Dental
Institute Scientific supervisor: Nurmatova I.B., PhD, Associate Professor of the
Department of Dermatovenereology and Cosmetology
Tashkent State Dental Institute, Uzbekistan
Abstract.
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) represent the two
most prevalent forms of non-melanoma skin cancer. Although both arise from keratinocytes,
they differ in etiology, clinical behavior, histopathology, and management strategies. This
thesis explores the pathogenesis, risk factors, clinical presentations, diagnostic techniques, and
current treatment modalities for BCC and SCC, highlighting their differences and implications
for patient prognosis. Particular emphasis is placed on recent advances in targeted therapies
and immunomodulatory treatment.
1.
Introduction.
Non-melanoma skin cancers (NMSCs) account for the majority of
malignancies diagnosed globally, with BCC and SCC comprising approximately 80% and
20% of cases respectively. These tumors are predominantly caused by ultraviolet (UV)
radiation-induced DNA damage, with additional contributions from immunosuppression,
chronic wounds, and genetic predispositions. Understanding their distinct biological behavior
is critical for optimizing management and reducing recurrence or metastasis.
2.
Etiology and Risk Factors
2.1 Basal Cell Carcinoma (BCC):
-
UV-B radiation as primary mutagenic factor (notably p53 mutations)
-
Association with PTCH1 gene mutations (Hedgehog signaling pathway dysregulation)
-
Common in fair-skinned individuals (Fitzpatrick skin types I-II)
-
Ionizing radiation, arsenic exposure, immunosuppression (e.g., organ transplant recipients)
2.2 Squamous Cell Carcinoma (SCC):
-
Cumulative UV exposure and actinic keratosis as precursor lesions
-
HPV infection (notably HPV-16, -18) in anogenital and periungual regions
-
Chronic inflammatory skin disorders (e.g., hidradenitis suppurativa)
-
Smoking, immunosuppression, and genetic syndromes (e.g., xeroderma pigmentosum)
3.
Clinical Features and Diagnostic Approach
3.1 BCC:
-
Presents as pearly, translucent papules with telangiectasias
-
Slow-growing, locally invasive, rarely metastatic
-
Common subtypes: nodular, superficial, morpheaform (sclerosing), pigmented 3.2 SCC:
-
Appears as hyperkeratotic, erythematous plaques or nodules, often ulcerated - Higher
metastatic potential than BCC, especially in immunosuppressed patients or tumors of the lip
and ear
-
Frequently arises from actinic keratoses or areas of chronic injury 3.3 Diagnosis:
-
Clinical evaluation followed by dermoscopy
106
-
Biopsy (shave, punch, or excisional)
-
Histopathology: BCC (basaloid cells with peripheral palisading, mucinous stroma); SCC
(keratin pearls, intercellular bridges, atypical squamous proliferation)
-
Imaging and sentinel node biopsy in advanced SCC cases
4. Management Strategies
4.1
Surgical Treatment:
-
Standard excision with histological margin assessment
-
Mohs micrographic surgery (particularly for BCC in cosmetically sensitive or recurrent cases)
-
Curettage and electrodesiccation (superficial lesions)
4.2 Non-surgical Treatments:
-
Topical therapies (imiquimod, 5-fluorouracil) for superficial BCC and SCC in situ
-
Photodynamic therapy (PDT)
-
Cryotherapy
4.3 Advanced and Metastatic Disease:
-
Radiation therapy for non-surgical candidates
-
Hedgehog pathway inhibitors (e.g., vismodegib, sonidegib) for advanced BCC - Systemic
chemotherapy and immune checkpoint inhibitors (e.g., cemiplimab) for advanced SCC
5. Prognosis and Follow-Up
-
BCC: Excellent prognosis, low recurrence with appropriate excision, negligible
metastasis risk
-
SCC: Variable prognosis based on size, depth, differentiation, and perineural invasion;
metastatic risk up to 5%
-
Regular dermatologic follow-up essential due to risk of recurrence or new primary
lesions
6. Recent Advances and Future Directions
-
Role of artificial intelligence in early detection
-
Biomarker development for treatment response prediction
-
Novel immunotherapeutic combinations
-
Genetic profiling to guide personalized therapy
Conclusion
BCC and SCC, despite originating from keratinocytes, exhibit distinct molecular pathways,
clinical behaviors, and therapeutic responses. Early recognition and precise histopathological
diagnosis remain essential for optimal management. The evolution of targeted therapies and
immunotherapies continues to enhance outcomes, particularly for advanced or recurrent
disease. Continued research into the molecular underpinnings of NMSCs promises to refine
individualized treatment approaches in the future.
REFERENCES:
1.
Шахизирова, И. Д., С. Р. Абдухамидова, and М. С. Шодиева. "Оптимизация
терапевтической тактика при лямблиозах у детей." Педиатрия 3 (2019): 104-106.
107
2.
Абдурахманова, С., Сулейманова, Н., Ходжаева, З., & Назарова, Д. (2022).
Особенности ультразвуковых и допплерометрических изменений у женщин с миомой
матки и/или аденомиозом и их роль в выборе метода лечения. in Library, 22(1), 44-47.
3.
Agzamova, Shoira. "Value of heart rate variability parameters in prognosis of
intrauterine infection of infants with cytomegalovirus." Medical Health and Science
Journal 4.4 (2010): 24-29.
4.
Abdusalamovna, Agzamova Shoira. "Factor analysis of cause-effect relationship of
fetal infections of children by the agents of TORCH—complex." European science review 5-
6 (2015): 43-46.
5.
Агзамова, Ш. "Артериальная гипертензия у детей: Полиморфизм BsmI
(rs1544410) гена VDR и витамина D." Актуальные вопросы практической
педиатрии 1.1 (2023): 17-19.
